Patents by Inventor Mark R. Player

Mark R. Player has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7829566
    Abstract: Quinazolines of the formula I in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent Claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: November 9, 2010
    Inventors: Werner Mederski, Ralf Devant, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R. Player, Edward Jaeger, Richard Soll
  • Patent number: 7790724
    Abstract: The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: September 7, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Mark R. Player, Nand Baindur, Benjamin Brandt, Naresh Chadha, Raymond J. Patch, Davoud Asgari, Taxiarchis M. Georgiadis
  • Patent number: 7728003
    Abstract: The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, n, Z, and R102 are described in the specification.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: June 1, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Mark R. Player, Hui Huang, Hu Huaping, Renee L. DesJarlais
  • Publication number: 20100113473
    Abstract: An aryl amide compound of Formula (I): or a pharmaceutically acceptable form thereof is disclosed. The compound is an ACC inhibitor and therefore useful in treating an ACC-mediated condition.
    Type: Application
    Filed: October 20, 2009
    Publication date: May 6, 2010
    Inventors: Mark R. Player, Jian Liu
  • Publication number: 20100093788
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein W1, W2, W3, R1, R1a, R2, R2a, R3, V, Q, and X are defined herein.
    Type: Application
    Filed: October 9, 2009
    Publication date: April 15, 2010
    Inventors: Mark R. Player, Daniel J. Parks, William Parsons, Senath K. Meegalla, Carl R. Illig, Shelley K. Ballentine
  • Patent number: 7642270
    Abstract: The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, Z, R101 and R200 are described in the specification.
    Type: Grant
    Filed: September 12, 2006
    Date of Patent: January 5, 2010
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Mark R. Player, Hui Huang, Daniel A. Hutta, Renee L. DesJarlais
  • Patent number: 7612211
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 3, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Wing S. Cheung, Daniel J. Parks, William H. Parsons, Sharmila Patel, Mark R. Player
  • Patent number: 7608622
    Abstract: The invention is directed to compounds of Formula I: wherein Q, Y, A are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein kinases, especially Aurora-1, Aurora-2 and Aurora-3 kinases.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: October 27, 2009
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jian Liu, Raymond J. Patch, Mark R. Player, Huaping Hu
  • Patent number: 7547702
    Abstract: Quinazolines of the formula (I) in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein 1bIX antagonists.
    Type: Grant
    Filed: September 17, 2001
    Date of Patent: June 16, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Werner Mederski, Maria Devant, legal representative, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R. Player, Edward Jaegar, Richard Soll, Ralf Devant
  • Patent number: 7446210
    Abstract: The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.
    Type: Grant
    Filed: October 24, 2005
    Date of Patent: November 4, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Tho V. Thieu, Yu-Kai Lee, Daniel J. Parks, Thomas P. Markotan, Wenxi Pan, Karen L. Milkiewicz, Mark R. Player
  • Patent number: 7429603
    Abstract: The invention is directed to compounds of Formulae I, II and III: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: September 30, 2008
    Assignee: 3-Dimensional Pharmaceuticals, Inc.
    Inventors: Mark R. Player, Nand Baindur, Benjamin Brandt, Naresh Chadha, Raymond J. Patch, Davoud Asgari, Taxiarchis M. Georgiadis
  • Patent number: 7427683
    Abstract: The invention is directed to compounds of Formulae I: wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: September 23, 2008
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Mark R. Player, Nand Baindur, Benjamin Brandt, Naresh Chadha, Raymond J. Patch, Davoud Asgari, Taxiarchis Georgiadis
  • Publication number: 20080146637
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: December 12, 2007
    Publication date: June 19, 2008
    Inventors: Wing S. Cheung, Daniel J. Parks, William H. Parsons, Sharmila Patel, Mark R. Player
  • Patent number: 7326788
    Abstract: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: February 5, 2008
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Mark J. Wall, Mark R. Player, Raymond Joseph Patch, Sanath Meegalla, Jian Liu, Carl R. Illig, Wing Cheung, Jinsheng Chen, Davoud Asgari
  • Publication number: 20070259936
    Abstract: The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.
    Type: Application
    Filed: April 13, 2007
    Publication date: November 8, 2007
    Inventors: Mark R. Player, Scott L. Dax, William H. Parsons, Michael Richard Brandt, Raul R. Calvo, Sharmila Patel, Jian Liu, Wing S. Cheung, Michele C. Jetter, Yu-Kai Lee, Mark A. Youngman, Wenxi Pan, Kenneth M. Weils, Derek A. Beauchamp
  • Publication number: 20040110758
    Abstract: The invention is directed to compounds of Formulae I, II, III or IV: 1
    Type: Application
    Filed: September 30, 2003
    Publication date: June 10, 2004
    Inventors: Mark R. Player, Nand Baindur, Benjamin Brandt, Davoud Asgari, Naresh Chadha
  • Publication number: 20040044204
    Abstract: Quinazolines of the formula I, in which R, R1, R2, R3, R4 and Y have the meaning indicated in Patent claim 1, and their salts or solvates as glycoprotein IbIX antagonists.
    Type: Application
    Filed: March 20, 2003
    Publication date: March 4, 2004
    Inventors: Werner Mederski, Ralf Devant, Gerhard Barnickel, Sabine Bernotat-Danielowski, James Vickers, Bertram Cezanne, Daljit Dhanoa, Bao-Ping Zhao, James Rinker, Mark R Player, Edward Jaeger, Richard Soll
  • Patent number: 6214805
    Abstract: The present invention relates to methods of inhibiting infection by RNA viruses with complexes of an activator of RNase L and an oligonucleotide that is capable of binding to the genome, antigenome or mRNAs of a negative strand RNA virus to specifically cleave the genomic or antigenomic RNA strand of the virus. In accordance with the present invention, the methods and complexes of the invention may be applied to target any negative strand RNA virus. The invention in one embodiment relates to a covalently linked complex of an oligonucleotide that is capable of binding to the genomic or antigenomic template RNA strand of a negative strand RNA virus and/or binding to an mRNA of a viral protein (an “antisense oligonucleotide”) coupled to an activator of RNase L. In a preferred embodiment of the present invention, the oligonucleotide component of the complex is complementary to a region of the viral genomic RNA strand characterized by repeated or consensus sequences.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: April 10, 2001
    Assignees: The United States of America as represented by the Department of Health and Human Services, The Cleveland Clinic Foundation
    Inventors: Paul F. Torrence, Robert Hugh Silverman, Nick Mario Cirino, Guiying Li, Wei Xiao, Mark R. Player